Japan has quietly turned its HTA framework into one of the most influential, but often misunderstood, pricing systems in major markets. Since formal cost-effectiveness evaluation became part of the NHI price-setting process in 2019, the country has refined its approach almost every year. The 2024-25... Continue reading
Return to previous page
Page 4
For years, the United States and the United Kingdom have stood on opposite ends of the drug pricing spectrum. The US has historically allowed manufacturers to set list prices with relatively few constraints, while the UK’s NHS relies on strict cost effectiveness evaluations through NICE.... Continue reading
Background: A biopharma company was preparing to launch a first-in-class therapy in immunology TA. The asset showed strong clinical promise, but its commercial team faced a familiar challenge: every market had different payer expectations, and a single misstep on price in one country could trigger... Continue reading
Introduction: A US-based mid-size biotech firm was preparing for its upcoming investment cycle to broaden its therapeutic area focus. The team had strong scientific instincts but lacked a unified, evidence-based approach to compare opportunities across disease areas, evaluate commercial risk, and pressure-test assumptions in volatile... Continue reading
Introduction: A global biopharma company preparing to advance towards asset commercialisation approached Thelansis with a clear priority that they wanted to enter multiple markets with confidence that their clinical evidence, pricing expectations, and value communication would withstand payer scrutiny. The therapy showed strong early promise,... Continue reading
2025 almost felt like pharma pressed a reset button on dealmaking. Money moved in patches, a handful of blockbuster deals grabbed headlines and reshaped competitive positions, while the broader market kept its cautionary posture. If you follow the industry, two impressions stand out: (1) big... Continue reading
Introduction: During 2024, a mid-sized biopharma company from the European region was developing a novel systematic therapy for the treatment of IPF, seeking an evidence-backed structured partnership strategy, where EpiLansis played an instrumental role in validating the market assumptions, estimating the market potential, and identifying... Continue reading
With the healthcare landscape shifting rapidly, teams across biopharma, consulting, med-tech, and healthcare strategy face a common bottleneck: turning scattered epidemiology data, literature, real world data and competitive signals into clear, actionable insights. Epidemiology remains the backbone of clinical development, commercial planning, medical strategy, and... Continue reading
The U.S. healthcare system never really sits still but 2026 is shaping up to be a year where cost, access, and innovation intersect in new and sometimes uncomfortable ways. From the Inflation Reduction Act’s pricing negotiations to the quiet but powerful spread of value-based models,... Continue reading
In the fast‐moving world of biopharma innovation, it’s easy to get excited by the science – the novel target, the breakthrough molecule, the cutting-edge modality. But amid that excitement, one strategic document often gets overlooked or relegated to a checkbox: the Target Product Profile (TPP).... Continue reading
More
More
- Report & Insights
- Strategy Products
Strategy Products
- Consulting Services
- Media
Media
